Spinal Muscular Atrophy

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 499-506

  Oskoui, Maryam ^a   Kaufmann, Petra ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

clinical trials; Spinal muscular atrophy

Indexed keywords

ACETYLCARNITINE; ANTACID AGENT; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; CARNITINE; CREATINE; GABAPENTIN; HYDROXYUREA; LENTIVIRUS VECTOR; PALIVIZUMAB; PNEUMOCOCCUS VACCINE; PROTIRELIN; RILUZOLE; SALBUTAMOL; SURVIVAL MOTOR NEURON PROTEIN; VALPROIC ACID; VIRUS GLYCOPROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASPIRATION PNEUMONIA; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DISEASE MARKER; DISEASE SEVERITY; DNA MODIFICATION; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC SCREENING; GENETIC VARIABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HYDROTHERAPY; LUNG DISEASE; MUSCLE STRENGTH; MUSCLE STRETCHING; MUTATIONAL ANALYSIS; NERVE FIBER TRANSPORT; NERVE GROWTH; NERVE TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE THERAPY; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SPINAL MUSCULAR ATROPHY; STOMACH FUNCTION DISORDER; STOMACH TUBE; STREPTOCOCCUS PNEUMONIA; SURVIVAL TIME; TRANSGENIC MOUSE; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; MUSCULAR ATROPHY, SPINAL; ORPHAN DRUG PRODUCTION; PATIENT SELECTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 53049108198     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.08.007     Document Type: Article

References (74)

1. Hoffmann J. Über chronische spinale Muskelatrophie im Kindesalter, auf familiärer Basis. [On chronic spinal muscular atrophy in childhood, with a familial basis; in German]. Dtsch Z Nervenheilkd 3 (1893) 427-470
2. Werdnig G. Zwei frühinfantile hereditäre Fälle von progressiver Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage. [Two early infantile hereditary cases of progressive muscular atrophy simulating dystrophy, but on a neural basis; in German]. Arch Psychiatr Nervenkr 22 (1891) 437-480
3. Gilliam T.C., Brzustowicz L.M., Castilla L.H., et al. Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature 345 (1990) 823-825
4. Lefebvre S., Bürglen L., Reboullet S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80 (1995) 155-165
5. Feldkötter M., Schwarzer V., Wirth R., Wienker T.F., and Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70 (2002) 358-368
6. Crawford T.O. Spinal muscular atrophies. In: Jones H.R., De Vivo D.C., and Darras B.T. (Eds). Neuromuscular disorders of infancy, childhood, and adolescence: a clinician's approach (2003), Butterworth-Heinemann, Philadelphia 145-166
7. Oskoui M., Levy G., Garland C.J., et al. The changing natural history of spinal muscular atrophy type 1. Neurology 69 (2007) 1931-1936
8. Iannaccone S.T., Smith S.A., and Simard L.R. Spinal muscular atrophy. Curr Neurol Neurosci Rep 4 (2004) 74-80
9. Liu Q., and Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 15 (1996) 3555-3565
10. Feng W., Gubitz A.K., Wan L., et al. Gemins modulate the expression and activity of the SMN complex. Hum Mol Genet 14 (2005) 1605-1611
11. Pellizzoni L., Yong J., and Dreyfuss G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 298 (2002) 1775-1779
12. Setola V., Terao M., Locatelli D., Bassanini S., Garattini E., and Battaglia G. Axonal-SMN (a-SMN), a protein isoform of the survival motor neuron gene, is specifically involved in axonogenesis. Proc Natl Acad Sci U S A 104 (2007) 1959-1964
13. Zhang H., Xing L., Rossoll W., Wichterle H., Singer R.H., and Bassell G.J. Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons. J Neurosci 26 (2006) 8622-8632
14. Chan Y.B., Miguel-Aliaga I., Franks C., et al. Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum Mol Genet 12 (2003) 1367-1376
15. Rajendra T.K., Gonsalvez G.B., Walker M.P., Shpargel K.B., Salz H.K., and Matera A.G. A Drosophila melanogaster model of spinal muscular atrophy reveals a function for SMN in striated muscle. J Cell Biol 176 (2007) 831-841
16. Wang C.H., Finkel R.S., Bertini E.S., et al. Participants of the International Conference on SMA Standard of Care. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22 (2007) 1027-1049
17. Bach J.R., and Bianchi C. Prevention of pectus excavatum for children with spinal muscular atrophy type 1. Am J Phys Med Rehabil 82 (2003) 815-819
18. Bach J.R., Niranjan V., and Weaver B. Spinal muscular atrophy type 1: a noninvasive respiratory management approach. Chest 117 (2000) 1100-1105
19. Tefft D., Guerette P., and Furumasu J. Cognitive predictors of young children's readiness for powered mobility. Dev Med Child Neurol 41 (1999) 665-670
20. Jones M.A., McEwen I.R., and Hansen L. Use of power mobility for a young child with spinal muscular atrophy. Phys Ther 83 (2003) 253-262
21. Thoumie P., Charlier J.R., Alecki M., et al. Clinical and functional evaluation of a gaze controlled system for the severely handicapped. Spinal Cord 36 (1998) 104-109
22. O'Hagen JM, Ryan P, Wei Y, Kaufmann P, De Vivo DC. The effect of a gravity neutral orthosis on disability in children with SMA type 1. Paper presented at: 11th Annual International Spinal Muscular Atrophy Research Group Meeting, Schaumburg, IL, June 21-23, 2007.
23. Russman B.S., Iannaccone S.T., and Samaha F.J. A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 60 (2003) 1601-1603
24. Wong B., Hynan L., Iannaccone S., et al. A randomized, placebo-controlled trial of creatine in children with spinal muscular atrophy. J Clin Neuromusc Dis 8 (2007) 101-110
25. Kinali M., Mercuri E., Main M., et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 59 (2002) 609-610
26. Angelozzi C., Borgo F., Tiziano F.D., Martella A., Neri G., and Brahe C. Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 45 (2008) 29-31
27. Azzouz M., Le T., Ralph G.S., et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 114 (2004) 1726-1731
28. Monani U.R., Lorson C.L., Parsons D.W., et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8 (1999) 1177-1183
29. Lorson C.L., Hahnen E., Androphy E.J., and Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 96 (1999) 6307-6311
30. Brichta L., Hofmann Y., Hahnen E., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12 (2003) 2481-2489
31. Grzeschik S.M., Ganta M., Prior T.W., Heavlin W.D., and Wang C.H. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 58 (2005) 194-202
32. Andreassi C., Angelozzi C., Tiziano F.D., et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 12 (2004) 59-65
33. Hirtz D., Iannaccone S., Heemskerk J., Gwinn-Hardy K., Moxley III R., and Rowland L.P. Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology 65 (2005) 1352-1357
34. Miller R.G., Moore D.H., Dronsky V., et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 191 (2001) 127-131
35. Merlini L., Solari A., Vita G., et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol 18 (2003) 537-541
36. Tzeng A.C., Cheng J., Fryczynski H., et al. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil 79 (2000) 435-440
37. Mercuri E., Bertini E., Messina S., et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 14 (2004) 130-135
38. Mercuri E., Bertini E., Messina S., et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 68 (2007) 51-55
39. Kaufmann P., and Finkel R. Learning to walk: challenges for spinal muscular atrophy clinical trials. Neurology 68 (2007) 11-12
40. Swoboda K.J., Kissel J.T., Crawford T.O., et al. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol 22 (2007) 957-966
41. Liang W.C., Yuo C.Y., Chang J.G., et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci 268 (2008) 87-94
42. Brichta L., Holker I., Haug K., Klockgether T., and Wirth B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 59 (2006) 970-975
43. Weihl C.C., Connolly A.M., and Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 67 (2006) 500-501
44. Munsat T., and Davies K. Spinal muscular atrophy. 32nd ENMC International Workshop. Naarden, 10-12 March 1995. Neuromuscul Disord 6 (1996) 125-127
45. Kaufmann P., Muntoni F., and International Coordinating Committee for SMA Subcommittee on SMA Clinical Trial Design. Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design. Neuromuscul Disord 17 (2007) 499-505
46. Iannaccone S.T. Outcome measures for pediatric spinal muscular atrophy. Arch Neurol 59 (2002) 1445-1450
47. Iannaccone S.T., Hynan L.S., and American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group. Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol 60 (2003) 1130-1136
48. Mercuri E., Messina S., Battini R., et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord 16 (2006) 93-98
49. Merlini L., Bertini E., Minetti C., et al. Motor function-muscle strength relationship in spinal muscular atrophy. Muscle Nerve 29 (2004) 548-552
50. Main M., Kairon H., Mercuri E., and Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 7 (2003) 155-159
51. De Gruttola V.G., Clax P., DeMets D.L., et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 22 (2001) 485-502
52. Lesko L.J., and Atkinson Jr. A.J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41 (2001) 347-366
53. -/- mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 9 (2000) 333-339
54. Le T.T., Pham L.T., Butchbach M.E., et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 14 (2005) 845-857
55. Frugier T., Tiziano F.D., Cifuentes-Diaz C., et al. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum Mol Genet 9 (2000) 849-858
56. El-Khodor B.F., Edgar N., Chen A., et al. Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp Neurol 212 (2008) 29-43
57. Winberg M., El-Khodor B., Ramboz S., et al. Beneficial effects of valproic acid (VPA) and hydroxyurea (HU) in a mouse model of spinal muscular atrophy (SMA). Neurology 68 Suppl 1 (2007) A403 (abstract)
58. Iannaccone S., Hynan L.S., and Group A. Challenges of enrollment for SMA type I clinical trials. Neuromuscul Disord 17 (2007) 780 (abstract)
59. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 15 (1978) 409-413
60. Kaufmann P., Finkel R., Darras B., et al., PNCR Network. The natural history of spinal muscular atrophy: preliminary results from the PNCR Network. Neuromuscul Disord 17 (2007) 776-777
61. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., et al., Northeast ALS Consortium. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61 (2003) 456-464
62. Gordon P.H., Moore D.H., Miller R.G., et al. Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6 (2007) 1045-1053
63. Reaman G.H. Clinical advances in pediatric hematology & oncology: cooperative group research. Clin Adv Hematol Oncol 3 (2005) 133-135
64. Widemann B.C., Balis F.M., Shalabi A., et al. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst 96 (2004) 1557-1559
65. Reaman G.H. Pediatric cancer research from past successes through collaboration to future transdisciplinary research. J Pediatr Oncol Nurs 21 (2004) 123-127
66. Kennedy G.E., Peersman G., and Rutherford G.W. International collaboration in conducting systematic reviews: the Cochrane Collaborative Review Group on HIV Infection and AIDS. J Acquir Immune Defic Syndr 30 Suppl 1 (2002) S56-S61
67. Levy G., Kaufmann P., Buchsbaum R., et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 66 (2006) 660-663
68. Kaufmann P., Levy G., Montes J., et al., QALS Study Group. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler 8 (2007) 42-46
69. Nayak M.S., Kim Y.S., Goldman M., Keirstead H.S., and Kerr D.A. Cellular therapies in motor neuron diseases. Biochim Biophys Acta 1762 (2006) 1128-1138
70. Wichterle H., Lieberam I., Porter J.A., and Jessell T.M. Directed differentiation of embryonic stem cells into motor neurons. Cell 110 (2002) 385-397
71. Gao J., Coggeshall R.E., Chung J.M., Wang J., and Wu P. Functional motoneurons develop from human neural stem cell transplants in adult rats. Neuroreport 18 (2007) 565-569
72. Gao J., Coggeshall R.E., Tarasenko Y.I., and Wu P. Human neural stem cell-derived cholinergic neurons innervate muscle in motoneuron deficient adult rats. Neuroscience 131 (2005) 257-262
73. Harper J.M., Krishnan C., Darman J.S., et al. Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci U S A 101 (2004) 7123-7128
74. Deshpande D.M., Kim Y.S., Martinez T., et al. Recovery from paralysis in adult rats using embryonic stem cells. Ann Neurol 60 (2006) 32-44